Sara N. Hanson

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19

Raymund R. Razonable, Colin Pawlowski, John C. O’Horo et al. · EClinicalMedicine · 2021 · 134 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8

Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019

Ravindra Ganesh, Lindsey M. Philpot, Dennis M. Bierle et al. · The Journal of Infectious Diseases · 2021 · 102 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +10

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19

Raymund R. Razonable, Nicole C.E. Aloia, Ryan J. Anderson et al. · Mayo Clinic Proceedings · 2021 · 54 citations · Full text

Pharmacy, Health Informatics, Infectious Diseases +17

Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19

Dennis M. Bierle, Ravindra Ganesh, Caroline G. Wilker et al. · Journal of Primary Care & Community Health · 2021 · 50 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +16

Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

Dennis M. Bierle, Ravindra Ganesh, Sidna M. Tulledge‐Scheitel et al. · The Journal of Infectious Diseases · 2021 · 49 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16